Viva Biotech has established in vitro pharmacology platforms, including drug target validation, assay development, and compound screening services.
In vitro pharmacology is led by Dr. Derek Ren who has 10 years of drug discovery research with Pfizer. Joining Derek are numerous directors and group leaders with many years experience in assay development and target validation. With talented research teams, we provide a broad spectrum of quality services and in-depth biological support for integrated drug discovery programs to global pharmaceutical companies and biotech companies.
Services:
Drug Target Validation
SiRNA-mediated gene knock down
Lentiviral ShRNA-mediated gene knock down
Assay Development
Targets types:
G-protein coupled receptors (GPCR)
Kinases
Enzymes: HMTase, HDACs, etc
Nuclear receptors
Ion channels
Assay types:
Cell-based assays
Biochemical assays
Detection formats
Fluorescence
FLIPR
FP
FACS
ELISA
LCMS
UV-Vis
Luminescence
Radioactive binding assay
Compound Screening:
Viva provides the highest quality and customized compound screening service in both 96-well and 384-well format. We offer 45 in-house developed GRCR stable cell lines and 53 human cancer cell lines which have been validated in cell-based functional assays.